ASCOT-BLPA
An antihypertensive regimen of amlodipine with added perindopril significantly reduces all-cause mortality and most major adverse cardiovascular outcomes compared with a regimen of atenolol with the addition of a diuretic, according to the final results of ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm).
An antihypertensive regimen of amlodipine with added perindopril significantly reduces all-cause mortality and most major adverse cardiovascular outcomes compared with a regimen of atenolol with the addition of a diuretic, according to the final results of ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm). The results from ASCOT-BPLA were presented at the European Society of Cardiology Congress 2005 in Stockholm, Sweden.
The ASCOT-BPLA included 19,257 patients with hypertension who had at least 3 other cardiovascular risk factors. Patients were randomized to either 5 to 10 mg of amlodipine with 4 to 8 mg of perindopril as required or 50 to 100 mg of atenolol with the addition of 1.25 to 2.5 mg of bendroflumethiazide and potassium as required.
The primary end point was nonfatal MI and fatal coronary heart disease (CHD).
The amlodipine/perindopril strategy conferred an advantage in all prespecified subgroups, said Neil R. Poulter, MD, co-investigator of ASCOT and professor of preventive cardiology medicine, Imperial College London.
There was a mean blood pressure difference of 2.7/1.9 mmHg throughout the trial in favor of the amlodipine/ perindopril regimen. "Blood pressure differences are unlikely to be a single explanation," said Dr Poulter. "Blood pressure accounted for about 15% of the coronary differences and 30% of the stroke differences."
When using a technique called serial mean matching, which includes only those patients with similar systolic blood pressures during the trial, the incidences of coronary events and strokes were still less with the amlodipine/ perindopril strategy, he said.
"Given the large population burden of hypertension, even modest incremental benefits of specific agents over others can translate into an important public-health impact," said Salim Yusuf, DPhil, professor of medicine and director, division of cardiology, McMaster University, Ontario, Canada.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
